MeSH D000741 - aplastic anemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000080983:Bone marrow failure disorders
0 Companies
0 Drugs
Success rate
D000740:Anemia
D000741:
Aplastic anemia
D029502:Hypoplastic anemia congenital
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Eltrombopag olamine | Promacta | 2022-11-20 | 2008-11-20 | $2,052 M | Q2/20-Q2/23 |
| Eltrombopag | Revolade | 2010-03-11 | ||||
| Teva | Eltrombopag | Alvaiz | 2023-11-29 |
Clinical Trials
Historical Success Rate
Phase 1
94%32/34
Phase 2
33%19/58
Phase 3
28%5/18
Approved: 2Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use